NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Cantor Fitzgerald Pounding Table on NeuroPace Inc (NPCE): 'we would be buyers of NPCE on today's pullback'
May 27, 2025 1:05 PM EDTCantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $16.00 price target on NeuroPace Inc (NASDAQ: NPCE).
The analyst comments "Investment Summary. Today (5/27), Overweight-rated NeuroPace (NPCE) announced preliminary one-year results from its NAUTILUS study evaluating the RNS System in patients with idiopathic generalized epilepsy (IGE). While the study did not meet its primary effectiveness endpoint in the overall... More
